Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Stock Has Average Price Target of $5.40 According to Analysts
Inhibikase Therapeutics, Inc. (NASDAQ:IKT – Get Free Report) has been assigned an average recommendation of “Buy” from the nine research firms that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating, four have issued a buy rating and three have issued […]
5 Oct 09:58 · The Markets Daily